Effect of a Smoking Cessation Program on Sexual Function Recovery Following Robotic Prostatectomy at Kaiser Permanente Southern California

• Published in: Permanente journal Vol. 21; no. 2; pp. 16 - 138
• Main Authors: Safavy, Seena, Kilday, Patrick S, Slezak, Jeff M, Abdelsayed, George A, Harrison, Teresa N, Jacobsen, Steven J, Chien, Gary W
• Format: Journal Article
• Language: English
• Published: United States The Permanente Journal 2017
• Subjects: California; Erectile Dysfunction - epidemiology; Erectile Dysfunction - therapy; Follow-Up Studies; Humans; Male; Middle Aged; Original Research & Contributions; Prostatectomy - statistics & numerical data; Prostatic Neoplasms - epidemiology; Prostatic Neoplasms - surgery; Recovery of Function; Robotics; Smoking - epidemiology; Smoking - therapy; Smoking Cessation - statistics & numerical data
• ISSN: 1552-5767; 1552-5775
• DOI: 10.7812/TPP/16-138

The association between cigarette smoking and erectile dysfunction has been well established. Studies demonstrate improvements in erectile rigidity and tumescence as a result of smoking cessation. Radical prostatectomy is also associated with worsening of erectile function secondary to damage to the neurovascular bundles. To our knowledge, no previous studies have examined the relationship between smoking cessation after prostate cancer diagnosis and its effect on sexual function following robotic prostatectomy. We sought to demonstrate the utility of a smoking cessation program among patients with prostate cancer who planned to undergo robotic prostatectomy at Kaiser Permanente Southern California. All patients who underwent robotic prostatectomy between March 2011 and April 2013 with known smoking status were included, and were followed-up through November 2014. All smokers were offered the smoking cessation program, which included wellness coaching, tobacco cessation classes, and pharmacotherapy. Patients completed the Expanded Prostate Cancer Index Composite-26 (EPIC-26) health-related quality-of-life (HR-QOL) survey at baseline and postoperatively at 1, 3, 6, 12, 18, and 24 months. There were 2 groups based on smoking status: Continued smoking vs quitting group. Patient's age, Charlson Comorbidity Score, body mass index, educational level, median household income, family history of prostate cancer, race/ethnicity, language, nerve-sparing status, and preoperative/postoperative clinicopathology and EPIC-26 HR-QOL scores were examined. A linear regression model was used to predict sexual function recovery. A total of 139 patients identified as smokers underwent the smoking cessation program and completed the EPIC-26 surveys. Fifty-six patients quit smoking, whereas 83 remained smokers at last follow-up. All demographics and clinicopathology were matched between the 2 cohorts. Smoking cessation, along with bilateral nerve-sparing status, were the only 2 modifiable factors associated with improved sexual function after prostatectomy (6.57 points, p = 0.0226 and 8.97 points, p = 0.0485, respectively). In the setting of robotic prostatectomy, perioperative smoking cessation is associated with a significant improvement in long-term sexual functional outcome when other factors are adjusted.